Document is current
Any future updates will be listed below
-
Authors
Gao, Yuan
He, Xue-Yan https://orcid.org/0000-0001-5423-5997
Wu, Xiaoli S.
Huang, Yu-Han
Toneyan, Shushan
Ha, Taehoon https://orcid.org/0000-0002-4533-1140
Ipsaro, Jonathan J. https://orcid.org/0000-0002-2743-3776
Koo, Peter K. https://orcid.org/0000-0001-8722-0038
Joshua-Tor, Leemor https://orcid.org/0000-0001-8185-8049
Bailey, Kelly M.
Egeblad, Mikala https://orcid.org/0000-0002-3371-1445
Vakoc, Christopher R. https://orcid.org/0000-0002-1158-7180
- License Information
-
More Information
Article History
Received: 15 November 2021
Accepted: 24 November 2022
First Online: 19 January 2023
Competing interests
: C.R.V. has received consulting fees from Flare Therapeutics, Roivant Sciences and C4 Therapeutics; has served on the advisory boards of KSQ Therapeutics, Syros Pharmaceuticals and Treeline Biosciences; has received research funding from Boehringer-Ingelheim and Treeline Biosciences; and owns a stock option from Treeline Biosciences. M.E. is a member of the research advisory board for <i>brensocatib</i> for Insmed, Inc.; a member of the scientific advisory board for Vividion Therapeutics, Inc.; a consultant for Protalix, Inc.; and holds shares in Agios Pharmaceuticals, Inc. The remaining authors declare no competing interests.
